Becton, Dickinson: Q3 Earnings Insights

 

Shares of Becton, Dickinson BDX remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share were up 24.55% year over year to $2.74, which beat the estimate of $2.44.

Revenue of $4,890,000,000 higher by 26.85% from the same period last year, which beat the estimate of $4,510,000,000.

Guidance

The upcoming fiscal year's EPS expected to be between $12.85 and $12.95.

The upcoming fiscal year's revenue expected to be between $19,941,000,000 and $20,027,000,000.

Conference Call Details

Date: Aug 05, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/f7s46ik4

Recent Stock Performance

52-week high: $284.97

52-week low: $219.50

Price action over last quarter: Up 6.41%

Company Profile

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!